US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 1.650
  • 0.0000.00%
Close Nov 22 15:55 ET
  • 1.710
  • +0.060+3.64%
Pre 08:09 ET
31.11MMarket Cap-1755P/E (TTM)

Chemomab Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chemomab Therapeutics Q3 2024 Earnings Date

Currency：USDNov 14, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-<0.01
-0.20
-0.19
Miss Est.
+41.42%
+41.18%
-1920.20%
Analyst Rating
Strong Buy

Nov 15, 2024

Chemomab Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 14, 20242024/Q30.000 / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 14, 20242024/Q30.000 / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Chemomab Therapeutics Earnings Reports

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Nov 14 07:07 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Oct 11 16:04 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Aug 21 07:05 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Jul 25 08:13 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 15, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data